# Noboru Yamamoto

**Type:** Researchers  
**Canonical URL:** https://scholariq.org/researchers/noboru-yamamoto/

## Facts

| Field | Value |
| --- | --- |
| Citations | 18,456 |
| Field | Lung Cancer Treatments and Mutations |
| h-index | 67 |
| i10-index | 320 |
| Last Known Institution | National Cancer Centre Japan |
| OpenAlex ID | https://openalex.org/A5030587345 |
| ORCID iD | https://orcid.org/0000-0002-0787-2851 |
| Works | 1,233 |

## Researcher papers

- [Erlotinib alone or with bevacizumab as first-line therapy in patients with advanced non-squamous non-small-cell lung cancer harbouring EGFR mutations (JO25567): an open-label, randomised, multicentre, phase 2 study](https://scholariq.org/papers/erlotinib-alone-or-with-bevacizumab-as-first-line-therapy-in-patients-with/)
- [Vandetanib in patients with previously treated RET-rearranged advanced non-small-cell lung cancer (LURET): an open-label, multicentre phase 2 trial](https://scholariq.org/papers/vandetanib-in-patients-with-previously-treated-ret-rearranged-advanced-non-small/)
- [Lenvatinib in patients with advanced or metastatic thymic carcinoma (REMORA): a multicentre, phase 2 trial](https://scholariq.org/papers/lenvatinib-in-patients-with-advanced-or-metastatic-thymic-carcinoma-remora-a/)
- [First-in-Human, Phase I Dose-Escalation and Dose-Expansion Study of Trophoblast Cell-Surface Antigen 2–Directed Antibody-Drug Conjugate Datopotamab Deruxtecan in Non–Small-Cell Lung Cancer: TROPION-PanTumor01](https://scholariq.org/papers/first-in-human-phase-i-dose-escalation-and-dose-expansion-study-of-trophoblast/)
- [Phase I Dose-Escalation Study and Biomarker Analysis of E7080 in Patients with Advanced Solid Tumors](https://scholariq.org/papers/phase-i-dose-escalation-study-and-biomarker-analysis-of-e7080-in-patients-with/)
- [Association of antithyroglobulin antibodies with the development of thyroid dysfunction induced by nivolumab](https://scholariq.org/papers/association-of-antithyroglobulin-antibodies-with-the-development-of-thyroid/)
- [Reliability of Small Biopsy Samples Compared With Resected Specimens for the Determination of Programmed Death-Ligand 1 Expression in Non–Small-Cell Lung Cancer](https://scholariq.org/papers/reliability-of-small-biopsy-samples-compared-with-resected-specimens-for-the/)
- [PD-L1 expression in neuroendocrine tumors of the lung](https://scholariq.org/papers/pd-l1-expression-in-neuroendocrine-tumors-of-the-lung/)

## Researcher topics

- [Lung Cancer Treatments and Mutations](https://scholariq.org/topics/lung-cancer-treatments-and-mutations/)
- [Cancer Immunotherapy and Biomarkers](https://scholariq.org/topics/cancer-immunotherapy-and-biomarkers/)
- [HER2/EGFR in Cancer Research](https://scholariq.org/topics/her2-egfr-in-cancer-research/)
- [Lung Cancer Research Studies](https://scholariq.org/topics/lung-cancer-research-studies/)
- [Cancer Genomics and Diagnostics](https://scholariq.org/topics/cancer-genomics-and-diagnostics/)

## Researcher university

- [National Cancer Centre Japan](https://scholariq.org/institutions/national-cancer-centre-japan/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.